The clinical trial system needs to become more efficient at testing new molecules and bringing new products to market, Janet Woodcock, director of the Food and Drug Administration’s drug center, said Sept. 13.
“We aren’t set up to do clinical trials as an enterprise to screen things,” Woodcock, director of the FDA Center for Drug Evaluation and Research, said. “Trials are seen as a one-off.”
Woodcock was one of the speakers on a panel titled “Fostering Innovation & Job Growth” at a daylong forum, “Advancing Medical Innovation,” organized by Washington Post Live.
“It is widely known that we have...